Four patient claims for Heart Failure, each with the share of patients agreeing: treatment burden 72%, residual symptoms 65%, out-of-pocket cost 38%, day-to-day measures 29%.

• Treatment burden is how patients describe the conditionDaily tablets, titration visits and monitoring come before the symptoms.72%of patientsSurvey 202574%Preference 202466%HTA 2024cited›
• Symptom control still fails once therapy is optimisedBreathlessness and fatigue on exertion persist on full therapy.65%of patientsSurvey 202567%Preference 202459%HTA 2024cited›
• Out-of-pocket cost keeps regimens incompleteThe two branded foundational classes are the ones named when a pillar is skipped.38%of patientsPreference 202438%HTA 2024cited›
• Patients judge a therapy by the day, not by the endpointSleeping flat, walking further and fewer hospital days are the measures patients use.29%of patientsSurvey 202531%Preference 202424%›

Four physician and payer claims for Heart Failure, each with the share of physicians agreeing: titration limits 82%, a new class has to beat four 76%, access rules 61%, twice-daily adherence 54%.

• Target dose is missed for three reasons, not oneBlood pressure, renal function and potassium decide how far a regimen is titrated.82%of physiciansSurvey 202482%Claims 202522% on all fourKOLs2 of 2›
• A new class has to beat four, not beat placeboPhysicians judge an entrant on what it adds on top of quadruple therapy.76%of physiciansSurvey 202476%KOLs2 of 2›
• Adherence breaks at the twice-daily componentThe fourth class is not the concern; the twice-daily one is.54%of physiciansSurvey 202454%Patients 202444% of patientsKOLs1 of 2›
• Access rules decide when a newer class is startedA step through foundational therapy and an ejection-fraction cut shape the timing.61%of physiciansSurvey 202461%PayerconfirmedPayer1 of 1›